ESMO 2019 | Update on oncolytic viruses for cancer treatment

Kevin Harrington

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, gives us an update on oncolytic virotherapy, touching upon talimogene laherparepvec (T-VEC), the first oncolytic virus approved for the treatment of melanoma, before highlighting newer agents utilizing herpes simplex virus (HSV) with a transgene to modulate the immune response in multiple solid cancer types. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video